SARS-COv-2 spike glycoprotein is covered with glycans. Anti-glycan auto-antibodies are known to exist in humans and are implicated in autoimmune diseases (Bovin et al, BBA , 2012, p.1373) but are not yet implicated in multisystem imflammatory syndrome (MISC). MISC is correlated with SARS-2 antibodies. Is it reasonable to think SARS-2 particles that are transported to the germinal centers will stimulate maturation of naive B-cells that are anti-glycan? If so, then will a killed virus SARS-2 vaccine risk developing MISC?